Abstract
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers. Despite immunotherapy approved, SCLC is still associated with a poor prognosis and many patients relapse and develop drug resistance. Subsequent therapies are limited and the overall survival for recurrent SCLC is around 26 weeks. Anlotinib is a multi-target receptor tyrosine kinase inhibitor that can significantly inhibit angiogenesis. The ALTER 1202 trial showed anlotinib monotherapy has a longer median PFS compared with placebo (4.1 vs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
